Panbela Therapeutics, Inc., listed on the Nasdaq Stock Market, is set to be removed from listing effective May 6, 2024. The decision comes after a series of evaluations by Nasdaq Staff, which concluded that the company no longer meets certain listing requirements, specifically those under Listing Rules 5550(a)(2) and 5550(b)(1). Panbela Therapeutics was initially notified of the potential delisting on November 28, 2023, and subsequently requested a hearing on December 5, 2023. Despite receiving an additional delisting determination on January 22, 2024, for failing to meet the requirements of Listing Rule 5550(a)(4), the company's appeal to remain listed was denied by the Panel on March 5, 2024. Following a suspension of its securities on March 7, 2024, the company's request for reconsideration was also denied on March 15, 2024. With no further appeals made to the Nasdaq Listing and Hearing Review Council, the Staff's decision to delist became final on April 19, 2024.

Panbela Therapeutics, Inc., listed on the Nasdaq Stock Market, is set to be removed from listing effective May 6, 2024. The decision comes after a series of evaluations by Nasdaq Staff, which concluded that the company no longer meets certain listing requirements, specifically those under Listing Rules 5550(a)(2) and 5550(b)(1). Panbela Therapeutics was initially notified of the potential delisting on November 28, 2023, and subsequently requested a hearing on December 5, 2023. Despite receiving an additional delisting determination on January 22, 2024, for failing to meet the requirements of Listing Rule 5550(a)(4), the company's appeal to remain listed was denied by the Panel on March 5, 2024. Following a suspension of its securities on March 7, 2024, the company's request for reconsideration was also denied on March 15, 2024. With no further appeals made to the Nasdaq Listing and Hearing Review Council, the Staff's decision to delist became final on April 19, 2024.